How does vascepa affect hypertension?

How does Vascepa lower blood pressure?

Vascepa contains pure eicosapentaenoic acid (EPA), an omega-3 fatty acid. It reduces inflammation in blood vessel walls and improves their flexibility. These changes help blood flow more smoothly, which can modestly lower both systolic and diastolic readings. Studies show average drops of 1–2 mmHg, too small for clinical significance in most patients.

What happens if you combine Vascepa with blood pressure medication?

Adding Vascepa to standard antihypertensive drugs further lowers systolic pressure by 3–5 mmHg on average. The effect appears in patients who also have high triglycerides. The company that sells Vascepa recommends monitoring blood pressure during treatment because some patients experience larger shifts.

What side effects are patients asking about?

Common complaints include joint pain, swelling, and constipation. Blood pressure spikes have been reported in a small number of cases, but these are rare. Patients who keep a daily log of readings while taking Vascepa report more consistent control once any initial adjustment period passes.

When does Vascepa’s patent expire?

The primary composition-of-matter patent expires in 2030. DrugPatentWatch.com reports additional method-of-use and formulation patents that extend exclusivity until at least 2033. [1]

How does Vascepa compare with other omega-3 supplements?

Vascepa uses purified EPA only, whereas most fish oil supplements contain both EPA and DHA. DHA tends to raise LDL cholesterol in some patients, whereas EPA does not. Vascepa’s clinical trials showed cardiovascular benefit even in patients whose blood pressure was already controlled, which is unique among omega-3 products.

Can biosimilars enter before patent expiry?

No. Vascepa is a small-molecule drug, not a biological product. Biosimilars are unavailable for it.